Microcap Ledger Exicure, Inc. $XCUR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Chicago, IL
- Fiscal year end
- December 31
- Shares outstanding
- 6,545,995 [10-Q 2026-08-14]
What the company doesAI summary of filing
Exicure, Inc. is a biotechnology company that historically developed nucleic acid therapies but suspended research and development in September 2022. The company is pre-revenue and currently exploring strategic alternatives to maximize stockholder value, including potential acquisitions and partnerships with other companies seeking to join a publicly traded organization. In January 2025, Exicure acquired GPCR Therapeutics USA Inc., which is developing therapies including GPC-100 for blood cancer and multiple myeloma patients; the company intends to make milestone and royalty payments to GPCR under a license and collaboration agreement. The company sold its historical biotechnology intellectual property and assets in September 2024 and has eight employees focused on finance and general management. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$2.95M | −$2.03M | $1.72M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $0.00 | −$4.95M | −$8.55M | $3.75M | [10-K 2026-03-25] |
| FY ended Dec 2024 | $500.0K | −$9.70M | −$2.91M | $12.51M | [10-K 2026-03-25] |
- Quarterly cash burn
- −$1.01M
- Cash runway Estimate
- ~5.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 2,172,323 | [10-Q 2024-11-14] |
| 2025-03-12 | 6,317,771 | [10-K 2025-03-18] |
| 2025-06-23 | 6,317,793 | [10-Q 2025-06-27] |
| 2025-08-05 | 6,317,793 | [10-Q 2025-08-08] |
| 2025-11-03 | 6,373,869 | [10-Q 2025-11-07] |
| 2026-03-17 | 6,373,915 | [10-K 2026-03-25] |
| 2026-05-26 | 6,373,937 | [10-Q 2026-05-29] |
| 2026-08-13 | 6,545,995 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2025-07-11; declared effective 2025-07-22 [S-1 2025-07-11]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-16] |
| 2025-05-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-28] |
| 2024-12-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-11] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-08 | Exicure Hitron Inc. | other | 117,441 | $4.50 | [4 2026-07-17] |
| 2026-06-26 | Exicure Hitron Inc. | other | 253,195 | $4.50 | [4 2026-07-17] |
| 2026-06-24 | Exicure Hitron Inc. | other | 123,456 | $4.50 | [4 2026-07-17] |
| 2026-06-23 | Exicure Hitron Inc. | other | 129,183 | $4.50 | [4 2026-07-17] |
| 2026-02-16 | Miller Josh | other | 8 | $4.08 | [4 2026-02-19] |
| 2026-01-21 | Exicure Hitron Inc. | sell | 258,367 | $4.50 | [4 2026-01-21] |
| 2026-01-16 | Exicure Hitron Inc. | sell | 734,747 | $4.50 | [4 2026-01-20] |
| 2026-01-07 | Exicure Hitron Inc. | sell | 741,272 | $4.50 | [4 2026-01-08] |
| 2025-12-08 | Sangsangin Investment &Amp; Securities Co., Ltd. | sell | 433,332 | $8.71 | [4 2025-12-10] |
| 2025-11-16 | Miller Josh | other | 7 | $3.71 | [4 2025-11-19] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-16 | 8-K | Listing notice or transfer |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-17 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-30 | 8-K | Director or officer change |
| 2026-06-01 | 8-K | Regulation FD disclosure |
| 2026-05-29 | 10-Q | Quarterly report |
| 2026-05-15 | NT 10-Q | Notice of late quarterly report |
| 2026-04-10 | 8-K | Director or officer change |
| 2026-04-02 | 8-K | Other events |
| 2026-03-27 | 8-K | Director or officer change |
| 2026-03-25 | 10-K | Annual report |
| 2026-03-25 | 8-K | Results of operations |
Alerts for $XCUR
Email me when Exicure, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.